Jonathan M. Brotchie And NotAngleterre
List of bibliographic references
Number of relevant bibliographic references: 19.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000077 | Yilong Ma [États-Unis] ; Tom H. Johnston [Canada] ; Shichun Peng [États-Unis] ; Chuantao Zuo [République populaire de Chine] ; James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Yihui Guan [République populaire de Chine] ; David Eidelberg [États-Unis] ; Jonathan M. Brotchie [Canada] | Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. |
| 000787 | Karen L. Eskow Jaunarajs [États-Unis] ; David G. Standaert ; Tacey X. Viegas ; Michael D. Bentley ; Zhihao Fang ; Bekir Dizman ; Kunsang Yoon ; Rebecca Weimer ; Paula Ravenscroft ; Tom H. Johnston ; Michael P. Hill ; Jonathan M. Brotchie ; Randall W. Moreadith | Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit. |
| 000876 | Lorraine V. Kalia [Canada] ; Jonathan M. Brotchie ; Susan H. Fox | Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. |
| 000D50 | Philippe Huot [Canada] ; Tom H. Johnston ; Naomi P. Visanji ; Tayyeba Darr ; Donna Pires ; Lili-Naz Hazrati ; Jonathan M. Brotchie ; Susan H. Fox | Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. |
| 001089 | Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased Levels of 5-HT1A Receptor Binding in Ventral Visual Pathways in Parkinson's Disease |
| 001309 | James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
| 001944 | Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates |
| 001C27 | Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations |
| 001D22 | Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease |
| 001F06 | Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates |
| 001F39 | Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5-HT2A Receptors in the Temporal Cortex of Parkinsonian Patients with Visual Hallucinations |
| 002059 | Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada] | Serotonin and Parkinson's disease: On movement, mood, and madness |
| 002578 | Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada, Pays-Bas] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 002D72 | Giovanni Fabbrini [Italie] ; Jonathan M. Brotchie [Canada] ; Francisco Grandas [Espagne] ; Masahiro Nomoto [Japon] ; Christopher G. Goetz [États-Unis] | Levodopa‐induced dyskinesias |
| 003143 | Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure |
| 003277 | Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 003402 | Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L‐dopa–induced chorea, but not dystonia, in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 003652 | Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease |
| 003823 | Jonathan M. Brotchie [Canada] | Nondopaminergic mechanisms in levodopa‐induced dyskinesia |
| This area was generated with Dilib version V0.6.23. |  |